# Next‐level multiomics helps define new critical pathways in developmental hematopoiesis

**Authors:** David G. Kent

PMC · DOI: 10.1002/hem3.42 · HemaSphere · 2024-02-01

## Full-text entities

- **Genes:** KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, EPO (erythropoietin) [NCBI Gene 2056] {aka DBAL, ECYT5, EP, MVCD2}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, DEGS1 (delta 4-desaturase, sphingolipid 1) [NCBI Gene 8560] {aka DEGS, DEGS-1, DES1, Des-1, FADS7, HLD18}, CD34 (CD34 molecule) [NCBI Gene 947], EPOR (erythropoietin receptor) [NCBI Gene 2057] {aka EPO-R}, GATA1 (GATA binding protein 1) [NCBI Gene 2623] {aka CNSHA9, ERYF1, GATA-1, GF-1, GF1, HAEADA}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}
- **Diseases:** Cancer (MESH:D009369)
- **Chemicals:** sphingolipid (MESH:D013107), Lipid (MESH:D008055), Ceramide (MESH:D002518)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10878175/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC10878175/full.md

---
Source: https://tomesphere.com/paper/PMC10878175